GlaxoSmithKline Pharmaceuticals Limited GSK House, Dr. Annie Besant Road,

Worli, Mumbai - 400 030 Tel No: +91 22 2495 9595 Fax No: +91 22 2495 9494

Web: <a href="www.gsk-india.com">www.gsk-india.com</a>
Email: <a href="mailto:askus@gsk.com">askus@gsk.com</a>

22<sup>nd</sup> December 2025

To,

## **BSE LIMITED**

Phiroze Jeejeebhoy Towers Dalal Street Mumbai - 400001

## THE NATIONAL STOCK EXCHANGE OF INDIA LIMITED

CIN: L24239MH1924PLC001151

Exchange Plaza, 5<sup>th</sup> Floor, Plot No. C/1, G Block Bandra-Kurla Complex, Bandra (East) Mumbai - 400051

Dear Sir,

## Sub: Disclosure under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015

With reference to the captioned subject, we would like to inform you that the Company has received an Order from West Bengal State GST authorities, raising demand of Rs. 89,59,456/-. The relevant details to be disclosed is as under:

Sr no	Particulars	Details
1	Name of the authority	Joint Commissioner, State Tax, Large Taxpayer
		Unit, West Bengal.
2	Nature and details of the action(s) taken, initiated or order(s) passed	Demand Order dated 19th December 2025
		Total Demand Rs. 89,59,456/- (Tax -
		Rs.49,66,546; Interest – 34,96,256, and Penalty
		- Rs. 4,96,654)
3	Date of receipt of direction or order, including any	19th December 2025
	ad-interim or interim orders, or any other	
	communication from the authority	
4	Details of violation(s) / contravention(s) committed	The officer has raised demand in relation to GST
	or alleged to be committed	credit related issues, involving major issue of
		credit mismatch between Company's GST
		returns vis-à-vis details reported by suppliers.
5	Impact on financial, operation or other activities of	No impact on financial operations of the
	the listed entity, quantifiable in monetary terms to	Company. The Company is evaluating the
	the extent possible	demand order and will take appropriate actions in
		due course.

Note – The said demand Order has been received by the Company on 19<sup>th</sup> December 2025, i.e. on late Friday evening, hence submitting today.

Kindly take the same on the record.

Thanking you,

Yours faithfully

For GlaxoSmithKline Pharmaceuticals Limited

Ajay Nadkarni Vice President – Administration, Real Estate & Company Secretary